Publications
MENK Clinical Trials
Enkephalins--enhancement of active T-cell rosettes from lymphoma patients.Methionine enkephalin was found to increase significantly the active T-cell rosettes from lymphoma patients. In sharp contrast, the leucine enkephalin was observed to increase active rosettes only at a single low concentration. Neither enkephalin significantly altered the total T-cell rosettes. It is suggested that methionine enkephalin could have a significant influence in enhancing cell-mediated immunity and T-cell function, particularly in lymphoma patients
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This web site includes various"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities ExchangeAct of 1934, as amended, which represent the Company’s expectations or beliefsconcerning future events. Statements containing expressions such as “believes,”“anticipates,” “intends,” or “expects,” used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The CounterMarkets through the OTC Disclosure and News Service are intended to identifyforward-looking statements. All forward-looking statements involve risks anduncertainties. Although the Company believes its expectations are based uponreasonable assumptions within the bounds of its knowledge of its business andoperations, there can be no assurances that actual results will not differmaterially from expected results. The Company cautions that these and similarstatements included in this report are further qualified by important factorsthat could cause actual results to differ materially from those in theforward-looking statements. Readers are cautioned not to place undue relianceon forward-looking statements, which speak only as of the date thereof. TheCompany undertakes no obligation to publicly release any revisions to suchforward-looking statements to reflect events or circumstances after the date hereof.